Takeda Pharma and 3 other cos submit joint application to Japan min
Takeda Pharmaceutical Company Limited, AstraZeneca KK, Mitsubishi Tanabe Pharma Corporation and Eisai Co. Ltd have submitted a joint application to Japan’s ministry of Health, Labour and Welfare seeking approval of Helicobacter pylori gastritis.
This is like an additional indication for H. pylori eradication by concomitant therapy with four proton pump inhibitors iansonprazole, omeprazole, rabeprazole sodium and esomeprazole magnesium hydrate.
These pump inhibitors are manufactured and marketed by four companies in Japan under five brand names. The concomitant therapy includes a proton pump inhibitor, amoxicillin hydrate and either clarithromycin or metronidazole.
H.pylori gastritis is also known as chronic active gastritis due to the fact that it is causes histological gastric mucosal injury as a result of persistent infiltration of inflammatory cells in the gastric mucosa due to H.pylori infection.
Under the Japanese National Health Insurance system, the approved indications to eradicate H. pylori are presently limited to gastric and duodenalulcers, gastric MALTlymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic resection of early stage gastric cancer, the news reports said.
The four companies expect that once approved, the additional indication will significantly contribute to the prevention and treatment of diseases pertaining to H. pylori.
Takeda is a research-based global company having its main focus on pharmaceuticals. It is the largest pharmaceutical company in Japan and is also a global leader of the industry.